These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21333336)

  • 21. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long term prostate-specific antigen trends following subcapsular prostatectomy.
    Klausner AP; Anderson BB; Espy PG; Despradel VM; Grob BM
    Can J Urol; 2010 Dec; 17(6):5442-6. PubMed ID: 21172107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the size matter?: Prostate weight does not predict PSA recurrence after radical prostatectomy.
    Davidson DD; Koch MO; Lin H; Jones TD; Biermann K; Cheng L
    Am J Clin Pathol; 2010 Apr; 133(4):662-8. PubMed ID: 20231620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cryosurgical ablation of the prostate: high risk patient outcomes.
    Prepelica KL; Okeke Z; Murphy A; Katz AE
    Cancer; 2005 Apr; 103(8):1625-30. PubMed ID: 15747374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience.
    Koppie TM; Shinohara K; Grossfeld GD; Presti JC; Carroll PR
    J Urol; 1999 Aug; 162(2):427-32. PubMed ID: 10411051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen.
    Swanson GP; Du F; Michalek JE; Hermans M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):62-8. PubMed ID: 20646861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
    Zagars GK; Pollack A
    Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer.
    Vollmer RT; Humphrey PA
    Am J Clin Pathol; 2001 Dec; 116(6):864-70. PubMed ID: 11764075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
    Maffezzini M
    J Urol; 2005 Sep; 174(3):1151-2; author reply 1152. PubMed ID: 16094087
    [No Abstract]   [Full Text] [Related]  

  • 37. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.
    Spahn M; Joniau S; Gontero P; Fieuws S; Marchioro G; Tombal B; Kneitz B; Hsu CY; Van Der Eeckt K; Bader P; Frohneberg D; Tizzani A; Van Poppel H
    Eur Urol; 2010 Jul; 58(1):1-7; discussion 10-1. PubMed ID: 20299147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
    Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
    Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology.
    Polascik TJ; Nosnik I; Mayes JM; Mouraviev V
    Urology; 2007 Jul; 70(1):117-21. PubMed ID: 17656220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience.
    Barzell WE; Melamed MR
    Urology; 2007 Dec; 70(6 Suppl):27-35. PubMed ID: 18194708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.